Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01135-2
Abstract: Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this… read more here.
Keywords: exposed refractory; multiple myeloma; subgroup analysis; analysis ... See more keywords
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Comparative Effectiveness Research"
DOI: 10.57264/cer-2024-0236
Abstract: Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) of the… read more here.
Keywords: exposed refractory; treatment; patients triple; triple class ... See more keywords